Other mainly controllable adverse events such as thrombocytopenia, anemia, neutropenia, leukopenia, pruritus, rash, hand-foot syndrome, elevated AST/ALT, fatigue, nausea and vomiting, diarrhea, hypertension, proteinuria, and reactive cutaneous capillary endothelial cell proliferation, among others, did not result in serious adverse outcomes or lead to mortality. The gene discussed is GPT; the disease is Thrombocytopenia.